Theravance Biopharma, Inc. - Ordinary Shares (TBPH): Price and Financial Metrics
Today's Latest Price: $25.11 USD
May 27 4:00pm Add TBPH to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank TBPH Stock Summary The capital turnover (annual revenue relative to shareholder's equity) for TBPH is -0.56 -- better than merely 6.36% of US stocks. TBPH's price/sales ratio is 19.15; that's higher than the P/S ratio of 93.08% of US stocks. Equity multiplier, or assets relative to shareholders' equity, comes in at -2.78 for Theravance Biopharma Inc; that's greater than it is for just 4.06% of US stocks. If you're looking for stocks that are quantitatively similar to Theravance Biopharma Inc, a group of peers worth examining would be MXL, NVCN, LJPC, AGIO, and CLLS. TBPH's SEC filings can be seen here. And to visit Theravance Biopharma Inc's official web site, go to www.theravance.com. TBPH Price/Volume Stats
1.58B Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Company Bio
Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company was founded in 2013 and is based in George Town, the Cayman Islands.
TBPH Latest News Stream
All News Types Corp. News Debt Offering Downgrade Earnings Mgmt Change New Coverage (Bullish) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bearish) Rating Reiterated (Bullish) Resumes Coverage (Bullish) Stock Offering
Event/Time News Detail Loading, please wait... Latest TBPH News From Around the Web
Below are the latest news stories about Theravance Biopharma Inc that investors may wish to consider to help them evaluate TBPH as an investment opportunity.
Q1 2020 Theravance Biopharma Inc Earnings Call
TBPH earnings call for the period ending March 31, 2020.
Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.
Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More 'TBPH' Stories Here
TBPH Price Returns
9.85% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 1.1054 seconds.